ACC: Waiting on the FDA's heart-helping verdict, J&J shares more positive CV data for Invokana
admin 11th March 2018 Uncategorised 0ORLANDO, Fla.—Johnson & Johnson is waiting for word from the FDA on whether it’ll become the second diabetes drug in its class to snag an approval for cardiovascular risk reduction. But in the meantime, it’s trumpeting more outcomes data to support its case.
More: ACC: Waiting on the FDA's heart-helping verdict, J&J shares more positive CV data for Invokana
Source: fierce